Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/TP.0000000000002332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tacrolimus-induced cholestatic hepatotoxicity after renal transplantation: a case report.
J Med Case Rep
February 2024
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, 35113-19968, Iran.
Background: In this manuscript, we report a case of tacrolimus-associated hepatotoxicity in a kidney transplant recipient.
Case Presentation: In this case report, a 56 years old Arab male patient who received a kidney transplant presented with icterus, weakness, and lethargy two weeks after transplantation and tacrolimus initiation. In laboratory analysis hyperbilirubinemia and a rise in hepatic enzymes were observed.
Management of Tacrolimus-Induced Toxicity With Normal Serum Levels After Liver Transplant.
Exp Clin Transplant
January 2024
From the Department of Hepato-Gastroenterology, Sindh Institute of Urology and Transplantation (SIUT), Pakistan.
Drug-induced liver injury after liver transplant occurs in 1.7% of patients. Tacrolimus is an effective immunosuppressant that is used to treat acute rejection.
View Article and Find Full Text PDFIncidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study.
Front Pharmacol
March 2023
Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Rare data reported tacrolimus-induced liver injury (tac-DILI) in real world. We performed a nested case-control analysis of 1,010 renal transplant recipients. Recipients with tac-DILI were randomly matched at a ratio of 1:4 by the year of admission to the remaining recipients without tac-DILI to explore risk factors.
View Article and Find Full Text PDFTacrolimus-Induced Cholestatic Hepatitis in a Patient With Liver Transplant.
Transplantation
October 2018
PHE MD SAMU-Asturias, Oviedo, Spain.
Tacrolimus-induced severe cholestasis complicating renal transplantation.
Ren Fail
February 2014
Department of Nephrology and Clinical Transplantation, Institute of Kidney Diseases and Research Center, Dr. HL Trivedi Institute of Transplantation Sciences, Ahmedabad, India.
Tacrolimus, a calcineurin inhibitor, is a potent immunosuppressive agent used by a majority of transplanters across the globe. Its adverse effects include nephrotoxicity, neurotoxicity, new onset diabetes after transplant, gastro-intestinal toxicity, hepatotoxicity, and thrombotic microangiopathy. Tacrolimus-induced hepatotoxicity is a very uncommon side effect.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!